טמוקסיפן טבע 20 מג
teva israel ltd - tamoxifen as citrate - טבליה - tamoxifen as citrate 20 mg - tamoxifen - tamoxifen - for the palliative treatment of breast cancer generally in post menopausal women, either alone or in combination with other modalities.
טמוקסיפן טבע ® 20 מ"ג
teva pharmaceutical indust.ltd - tamoxifen as citrate 20 mg - tablets - tamoxifen - for the palliative treatment of breast cancer generally in post menopausal women, either alone or in combination with other modalities.
טמוקסיפן טבע ® 10 מ"ג
teva pharmaceutical indust.ltd - tamoxifen as citrate 10 mg - tablets - tamoxifen - for the palliative treatment of breast cancer generally in post menopausal women, either alone or in combination with other modalities.
פלוטין 20
teva israel ltd - fluoxetine as hydrochloride - קפסולות - fluoxetine as hydrochloride 20 mg - fluoxetine - fluoxetine - treatment of depression. obsessive-compulsive disorders (ocd). flutine is also indicated for the treatment of binge-eating and vomiting behaviors in bulimia nervosa.
פרוזק
eli lilly israel ltd, israel - fluoxetine as hydrochloride - קפסולות - fluoxetine as hydrochloride 20 mg - fluoxetine
ארומזין
pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.
אקסמסטאן טבע 25 מג
abic marketing ltd, israel - exemestane - טבליות מצופות פילם - exemestane 25 mg - exemestane - exemestane - exemestane teva® is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane teva® is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies.exemestane teva® is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy
ארימידקס
taro international ltd, israel - anastrozole - טבליות מצופות פילם - anastrozole 1.0 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
אנסטרוזול טבע
teva israel ltd - anastrozole - טבליה - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
אנסטרוזול טבע
teva israel ltd - anastrozole - טבליה - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.